menu
    • menu
    [{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Cytokinetics"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"MYH6_7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Aficamten","moa":"MYH6_7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"MYH6_7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Corxel Pharmaceuticals \/ Milestone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Milestone Pharmaceuticals"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Corxel Pharmaceuticals \/ Milestone Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Corxel Pharmaceuticals \/ Milestone Pharmaceuticals"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CX11","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CX11","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Corxel Pharmaceuticals \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Corxel Pharmaceuticals \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Corxel Pharmaceuticals \/ Oyster Point Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Oyster Point Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Corxel Pharmaceuticals \/ Oyster Point Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Oyster Point Pharma"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JX10","moa":"NF-\u03baB|p38 MAPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corxel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Corxel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Corxel Pharmaceuticals \/ Corxel Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Corxel Pharmaceuticals

    Menu

    Corxel Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CX11

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy & Safety of CX11 Tablets in Overweight & Obese Participants

                            Details : CX11 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2025

                            Lead Product(s) : CX11

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JX10

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Optimizing Reperfusion to Improve Outcomes and Neurologic Function

                            Details : JX10 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : JX10

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CX11

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CORXEL gets FDA Go-Ahead for Phase 2 Trial of CX11 in Obesity

                            Details : CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is being investigated for obesity and overweight.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : CX11

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VCT220

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Recipient : Vincentage Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CORXEL Acquires GLP-1 RA Rights for Obesity and Diabetes Treatment Worldwide

                            Details : Corxel acquires CX11 (VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and commercialization, from Vincentage.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 23, 2024

                            Lead Product(s) : VCT220

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Recipient : Vincentage Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cytokinetics Partners with Sanofi To Develop Aficamten in Greater China

                            Details : Sanofi will acquire CORXEL’s rights relating to CK-3773274 (aficamten) in Greater China> It is being evaluated for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 20, 2024

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese W...

                            Details : Aceclidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Presbyopia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

                            Details : Aficamten is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiomyopathy, Hypertrophic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 03, 2023

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

                            Details : Aceclidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Presbyopia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varenicline Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Oyster Point Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

                            Details : Varenicline Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2022

                            Lead Product(s) : Varenicline Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Oyster Point Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Corxel Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etripamil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Milestone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Etripamil in Healthy Subjects

                            Details : Etripamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : Etripamil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Milestone Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth